Eric Krauland

Eric Krauland

Auto-generated profile, based on publicly available information

Eric Krauland

A Adimab LLC , Lebanon , NH , USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 January 2015 in mAbs
Verified
Journal Article
Open access
HRHarald Rouha
Harald Rouha
ABAdriana Badarau
Adriana Badarau
ZVZehra C Visram
Zehra C Visram
MBMichael B Battles
Michael B Battles
BPBianka Prinz
Bianka Prinz
ENEszter Nagy
Eszter Nagy
Staphylococcus aureus is a major human pathogen associated with high mortality. The emergence of antibiotic resistance and the inability of antibiotics to counteract bacterial cytotoxins involved in the pathogenesis of S. aureus call for novel therapeutic approaches, such as passive immunization with monoclonal antibodies (mAbs). The complexity of staphylococcal pathogenesis and past failures with single mAb products represent considerable barriers for antibody-based therapeutics. Over the past few years, efforts have focused on neutralizing α-hemolysin. Recent findings suggest that the concerted actions of several cytotoxins, including the bi-component leukocidins play important roles in staphylococcal pathogenesis. Therefore, we aimed to isolate mAbs that bind to multiple cytolysins by employing high diversity human IgG1 libraries presented on the surface of yeast cells. Here we describe cross-reactive antibodies with picomolar affinity for α-hemolysin and 4 different bi-component leukocidins that share...

3 May 2019 in mAbs
Verified
Journal Article
Open access
MVMaximiliano Vasquez
Maximiliano Vasquez
EKEric Krauland
Eric Krauland
LWLaura Walker
Laura Walker
DWDane Wittrup
Dane Wittrup
TGTillman Gerngross
Tillman Gerngross
Two recent publications out of the same research laboratory report on structure-based in silico design of antibodies against viral targets without sequence disclosure. Cross-referencing the published data to patent databases, we established the sequence identity of said computationally designed antibodies. In both cases, the antibodies align with high sequence identity to previously reported antibodies of the same specificity. This clear underlying sequence relationship, which is far closer than the antibody templates reported to seed the computational design, suggests an alternative origin of the computationally designed antibodies. The lack of both reproducible computational algorithms and of output sequences in the initial publications obscures the relationship to previously reported antibodies, and sows doubt as to the genesis narrative described therein.